Does Pegasys Cause Depression?
Pegasys (peginterferon alfa-2a), used to treat hepatitis B and C, lists depression as a known side effect. Clinical trials and post-marketing data show it occurs in 18-40% of patients, depending on the study population and treatment duration—higher rates than placebo.[1][2] The risk stems from interferons' impact on brain serotonin levels and immune modulation, which can trigger mood changes.[3]
How Common Is Depression with Pegasys?
In pivotal trials for hepatitis C:
- Up to 40% of patients reported depression or mood disorders.
- Severe cases (suicidal ideation) affected 1-2%, leading to discontinuation in some.[2][4]
Combination with ribavirin (common regimen) increases incidence to 30-50%.[1] Hepatitis B trials showed lower rates, around 20%.[5]
Why Does It Happen and Who’s at Risk?
Interferons like Pegasys cross the blood-brain barrier, altering neurotransmitter balance and inflammation pathways, mimicking flu-like symptoms that escalate to depression.[3][6] Risk factors include:
- Pre-existing mental health history (2-3x higher risk).
- Female patients.
- Longer treatment (48 weeks vs. 24 weeks).[4][7]
What Do Patients Report?
Real-world data from FDA adverse event reports (FAERS) logs over 5,000 depression cases linked to Pegasys since approval, including 300+ suicides or attempts.[8] Patient forums note symptoms starting 4-8 weeks in, often resolving post-treatment but persisting in 5-10%.[9]
How Is It Managed During Treatment?
Screen for depression baseline; monitor with scales like PHQ-9. Antidepressants (SSRIs) are safe and effective in 70% of cases, started early.[7][10] Dose reduction or discontinuation if severe—guidelines recommend this for suicidal thoughts.[2]
Alternatives with Lower Depression Risk?